TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01395589
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
Study: NCT02774226
Drug: Tetrahydrobiopterin (BH4)
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 week intervention
Study: NCT01921257
Drug: Cat-PAD
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01061515
Drug: Intraperitoneal Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01061515
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00021697
Drug: AVP-923
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04220489
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
Study: NCT03569293
Drug: Placebo for Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken orally once a day
Study: NCT03569293
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken orally once a day
Study: NCT01734941
Drug: TSO
Normalized name: ENTsol
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
Study: NCT00092040
Drug: MK0217, alendronate sodium/Duration of Intervention: 12 mo
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01073527
Drug: Normal saline-salbutamol combination
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline - 4cc with salbutamol 0.5cc
Study: NCT00912015
Drug: Tramadol OAD
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00912015
Drug: Tramadol OAD 100mg
Normalized name: tramadol 100 MG
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02467907
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
Study: NCT02467907
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
Study: NCT02467907
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
Study: NCT00951496
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00951496
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IP
Study: NCT03790982
Drug: AD-35 60 mg
Normalized name: oxygen 35 %
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
Study: NCT01699594
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
Study: NCT02167633
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
Study: NCT03346668
Drug: Topical gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical gabapentin 6% solution
Study: NCT02105506
Drug: Tachosil patch
Normalized name: fibrinogen / thrombin Medicated Patch [TachoSil]
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04116931
Drug: Switch ticagrelor to clopidogrel
Normalized name: Ticagrelor
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
Study: NCT01806077
Drug: PZ-128
Normalized name: PZ-128
DrugBank: PZ-128 (DB11839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
Study: NCT03493685
Drug: sparsentan
Normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
Study: NCT03493685
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target dose of 300 mg daily
Study: NCT00951496
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IP
Study: NCT00951496
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02401750
Drug: Oxycodone Naltrexone (a)
Normalized name: naltrexone / oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02401750
Drug: Oxycodone Naltrexone (b)
Normalized name: naltrexone / oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03811223
Drug: Evolocumab Auto-Injector [Repatha]
Normalized name: evolocumab Auto-Injector [Repatha]
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab 140 mg every 2 weeks for 12 weeks
Study: NCT00951496
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IP
Study: NCT01253681
Drug: AMG 386, paclitaxel and carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
Study: NCT01294735
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
Study: NCT03504774
Drug: Cashew or Shrimp Oral Immunotherapy
Normalized name: Cashew
DrugBank: Shrimp (DB10567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
Study: NCT01857544
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly 2.0mg Aflibercept Intravitreal Injection
Study: NCT00186745
Drug: Tinzaparin
Normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
Study: NCT03015922
Drug: Lenalidomide or Pomalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
Study: NCT02273050
Drug: Saxagliptin 5 mg
Normalized name: sAXagliptin 5 MG
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Oral, 5 mg, Once daily in the morning
Study: NCT02273050
Drug: Placebo 5 mg for Saxagliptin
Normalized name: sAXagliptin 5 MG
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Oral, 5 mg, Once daily in the morning
Study: NCT02273050
Drug: Placebo 500 mg for metformin (with titration)
Normalized name: placebo 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Study: NCT02273050
Drug: Metformin 500 mg with titration
Normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Study: NCT00266721
Drug: Pancrelipase (Creon) 2 tablets with each meal
Normalized name: bone meal
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03084575
Drug: hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
Study: NCT00038701
Drug: TNP-470
Normalized name: TNP-470
DrugBank: TNP-470 (DB08633)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02874690
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
Study: NCT01670513
Drug: IDP-118 High Strength
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks
Study: NCT01028651
Drug: Treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min.
Study: NCT00905580
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150 mg orally
Study: NCT00905580
Drug: Vitamin Complex (placebo)
Normalized name: vitamin B complex
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin Complex 150 mg orally
Study: NCT01224730
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily
Study: NCT00648076
Drug: Divalproex Sodium Extended-Release Tablets 500 mg
Normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg, single dose fed
Study: NCT01026987
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
Study: NCT04344405
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D supplementation
Study: NCT01695057
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00678106
Drug: Dalbavancin
Normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
Study: NCT00032019
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
Study: NCT00032019
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/sq m PO bid days 1-5 of ea cycle
Study: NCT00032019
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
Study: NCT01758393
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03772561
Drug: AZD5363+Olaparib+Durvalumab
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
Study: NCT04504032
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
Study: NCT01504854
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
Study: NCT04657952
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
Study: NCT00788775
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00088868
Drug: alvespimycin hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Alvespimycin (DB12442)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00578864
Drug: Protracted Oral Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily
Study: NCT00578864
Drug: IV Bolus Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2
Study: NCT00578864
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1, 2, and 4
Study: NCT01671332
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV over 60 minutes, 75 mg/m2
Study: NCT01671332
Drug: Suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV over 30 minutes
Study: NCT01671332
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV over 60 minutes. 56 mg/m2
Study: NCT00578864
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard weight-based dosing with cyclophosphamide
Study: NCT00651976
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take by mouth at a dose of 2.5 mg on days 7-21
Study: NCT00077805
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04729088
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-anal application performed by the study physician of 2 g of the study drug
Study: NCT03002389
Drug: Anoro Ellipta
Normalized name: Anoro Ellipta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
Study: NCT03002389
Drug: Arnuity Ellipta
Normalized name: Arnuity Ellipta
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
Study: NCT00771459
Drug: Ropivacaine 0.5 %
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infiltration analgesia
Study: NCT03408873
Drug: Abilify Maintena
Normalized name: Abilify Maintena
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
Study: NCT03474133
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
Study: NCT01729403
Drug: aleglitazar
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mcg orally daily, 16 weeks
Study: NCT01729403
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
Study: NCT00532883
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
Study: NCT00532883
Drug: Magnesium Pidolate
Normalized name: magnesium pidolate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
Study: NCT00601588
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00086840
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00940342
Drug: GM-CSF (Sargramostim)
Normalized name: axatilimab-csfr
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg injection under the skin, three times a week for eight weeks.
Study: NCT00940342
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 administered intravenously once weekly for four weeks
Study: NCT02332356
Drug: azathioprine or adalimumab and infliximab
Normalized name: Infliximab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02273154
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
Study: NCT02273154
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDD patients with anxiety disorder take paroxetine (20-60mg/d)
Study: NCT00006222
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00315237
Drug: vinflunine and best supportive care
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
Study: NCT00000309
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03969901
Drug: Active Control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.
Study: NCT03665350
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile.
Study: NCT01667575
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antisecretary drug of the quadruple therapy
Study: NCT01667575
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic of the quadruple therapy
Study: NCT01667575
Drug: Bismuth Potassium Citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one of a component of a quadruple therapy